Inhibition of lysosomal functions reduces proteasomal activityLIYAN QIAO; JIANHUA ZHANG.Neuroscience letters. 2009, Vol 456, Num 1, pp 15-19, issn 0304-3940, 5 p.Article

An Historic Perspective of Proteasome InhibitionESSELTINE, Dixie-Lee; MULLIGAN, George.Seminars in hematology. 2012, Vol 49, Num 3, pp 196-206, issn 0037-1963, 11 p.Article

Discovery and Development of Second-Generation Proteasome InhibitorsKIRK, Christopher J.Seminars in hematology. 2012, Vol 49, Num 3, pp 207-214, issn 0037-1963, 8 p.Article

Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome InhibitionEVERLY, Matthew J; TERASAKI, Paul I; HOPFIELD, Judy et al.Transplantation. 2010, Vol 90, Num 12, pp 1493-1498, issn 0041-1337, 6 p.Conference Paper

Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical ExperienceMORAN, Eva; CARBONE, Federico; AUGUSTI, Valeria et al.Seminars in hematology. 2012, Vol 49, Num 3, pp 270-276, issn 0037-1963, 7 p.Article

Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5α B-box 2 domainDIAZ-GRIFFERO, Felipe; KAR, Alak; PERRON, Michel et al.Journal of virology. 2007, Vol 81, Num 19, pp 10362-10378, issn 0022-538X, 17 p.Article

Serendipity in discovery of proteasome inhibitorsDUNN, Derek; IQBAL, Mohamed; HUSTEN, Jean et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 10, pp 3503-3505, issn 0960-894X, 3 p.Article

Proteasome Inhibitors and Bone DiseaseQIANG, Ya-Wei; HEUCK, Christoph J; SHAUGHNESSY, John D et al.Seminars in hematology. 2012, Vol 49, Num 3, pp 243-248, issn 0037-1963, 6 p.Article

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitorZHAO, Wei-Li; LIU, Yan-Yan; SHEN, Zhi-Xiang et al.Blood. 2008, Vol 111, Num 7, pp 3867-3871, issn 0006-4971, 5 p.Article

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeDEMO, Susan D; KIRK, Christopher J; SHENK, Kevin D et al.Cancer research (Baltimore). 2007, Vol 67, Num 13, pp 6383-6391, issn 0008-5472, 9 p.Article

Durability of Antibody Removal Following Proteasome Inhibitor-Based TherapyEVERLY, Matthew J; TERASAKI, Paul I; TRIVEDI, Hargovind L et al.Transplantation. 2012, Vol 93, Num 6, pp 572-577, issn 0041-1337, 6 p.Article

The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In VivoDIWAN, Tayyab S; RAGHAVAIAH, Suresh; BURNS, Justin M et al.Transplantation. 2011, Vol 91, Num 5, pp 536-541, issn 0041-1337, 6 p.Article

Proteasome Inhibitors in Cancer Therapy : Lessons from the First Decade : The development of new cytotoxic agents in clinical oncologyORLOWSKI, Robert Z; KUHN, Deborah J.Clinical cancer research. 2008, Vol 14, Num 6, pp 1649-1657, issn 1078-0432, 9 p.Article

Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitorsKAIXU; ZHIYAN XIAO; YAN BO TANG et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 8, pp 2772-2774, issn 0960-894X, 3 p.Article

Macrocyclic Proteasome InhibitorsKRAHN, D; OTTMANN, C; KAISER, M et al.Current medicinal chemistry. 2011, Vol 18, Num 33, pp 5052-5060, issn 0929-8673, 9 p.Article

Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesisOLIVA, Joan; FRENCH, Samuel W; JUN LI et al.Experimental and molecular pathology. 2012, Vol 93, Num 1, pp 26-34, issn 0014-4800, 9 p.Article

Gα_12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulationYOON MEE YANG; LEE, Sanghwan; CHANG WON NAM et al.Carcinogenesis (New York. Print). 2010, Vol 31, Num 7, pp 1230-1237, issn 0143-3334, 8 p.Article

Role of Intracellular Calcium in Proteasome Inhibitor-Induced Endoplasmic Reticulum Stress, Autophagy, and Cell Death : Disease, Drug Metabolism, and Transporter InteractionsWILLIAMS, Jessica A; YIFENG HOU; NI, Hong-Min et al.Pharmaceutical research. 2013, Vol 30, Num 9, pp 2279-2289, issn 0724-8741, 11 p.Article

Proteasome inhibitors for cancer therapyIQBAL, Mohamed; MESSINA MCLAUGHLIN, Patricia A; DUNN, Derek et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 7, pp 2362-2368, issn 0968-0896, 7 p.Article

New betulinic acid derivatives as potent proteasome inhibitorsKEDUO QIAN; KIM, Sang-Yong; HUNG, Hsin-Yi et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 19, pp 5944-5947, issn 0960-894X, 4 p.Article

Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome InhibitorsTSCHAN, Serena; BROUWER, Arwin J; MORDMÜLLER, Benjamin et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 8, pp 3576-3584, issn 0066-4804, 9 p.Article

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceRUSCHAK, Amy M; SLASSI, Malik; KAY, Lewis E et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 13, pp 1007-1017, issn 0027-8874, 11 p.Article

Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome InhibitorsVALES-GOMEZ, Mar; CHISHOLM, Susan E; CASSADY-CAIN, Robin L et al.Cancer research (Baltimore). 2008, Vol 68, Num 5, pp 1546-1554, issn 0008-5472, 9 p.Article

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibitionJINSONG HU; NANA DANG; MENU, Eline et al.Blood. 2012, Vol 119, Num 3, pp 826-837, issn 0006-4971, 12 p.Article

High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome InhibitorsRUSHWORTH, Stuart A; BOWLES, Kristian M; MACEWAN, David J et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 5, pp 1999-2009, issn 0008-5472, 11 p.Article